KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Inventory (2016 - 2025)

Eli Lilly (LLY) has disclosed Inventory for 17 consecutive years, with $13.7 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Inventory rose 81.1% year-over-year to $13.7 billion, compared with a TTM value of $13.7 billion through Dec 2025, up 81.1%, and an annual FY2025 reading of $13.7 billion, up 81.1% over the prior year.
  • Inventory was $13.7 billion for Q4 2025 at Eli Lilly, up from $12.2 billion in the prior quarter.
  • Across five years, Inventory topped out at $13.7 billion in Q4 2025 and bottomed at $3.7 billion in Q1 2021.
  • Average Inventory over 5 years is $6.3 billion, with a median of $4.9 billion recorded in 2023.
  • The sharpest move saw Inventory decreased 2.37% in 2021, then skyrocketed 81.1% in 2025.
  • Year by year, Inventory stood at $3.9 billion in 2021, then rose by 10.9% to $4.3 billion in 2022, then surged by 33.95% to $5.8 billion in 2023, then surged by 31.46% to $7.6 billion in 2024, then surged by 81.1% to $13.7 billion in 2025.
  • Business Quant data shows Inventory for LLY at $13.7 billion in Q4 2025, $12.2 billion in Q3 2025, and $11.0 billion in Q2 2025.